Clinilabs is pleased to announce “Effect of lemborexant on sleep architecture in participants with insomnia disorder and mild obstructive sleep apnea” has recently been published in Sleep Medicine. This study focused on comorbid insomnia with obstructive sleep apnea (COMISA), highlighting its negative impact on daytime function and sleep quality.
Clete A. Kushida M.D., Ph.D. | Professor of Psychiatry and Behavioral Science | Stanford Medicine states, “COMISA has a debilitating effect on the ability of affected individuals to sleep well and invariably results in significant morbidity and mortality compared to those with obstructive sleep apnea or insomnia alone. The present study demonstrates the efficacy of lemborexant in improving sleep quantity and quality and highlights its utility as an important treatment option for patients suffering from COMISA.”
Study Summary: A phase 3 trial evaluated lemborexant (LEM), a dual-orexin-receptor antagonist, on sleep architecture in adults aged 55 and older with insomnia. Among the 1006 participants, 40.8% had mild obstructive sleep apnea. Results showed that both LEM doses (5 mg and 10 mg) significantly improved total sleep time (TST), and rapid eye movement (REM) sleep compared to placebo and zolpidem. These findings suggest that LEM is beneficial for patients struggling with insomnia and mild OSA.
Thank you, Gary Zammit, PhD for being part of this critical advancement in sleep medicine.
To view the full article, visit: https://loom.ly/of_lEzs